other material
confidence high
sentiment negative
materiality 0.65
Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00
REGENERON PHARMACEUTICALS, INC.
- Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.
- Charge expected to reduce both GAAP and non-GAAP diluted EPS by ~$1.00 in Q2 2026.
- Q2 2026 results not finalized; subject to financial statement closing procedures.
- Company does not forecast such IPR&D charges due to uncertainty of timing and magnitude.